Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

Authors Yawn BP, Li YF, Tian HJ, Zhang J, Arcona S, Kahler KH

Published Date June 2013 Volume 2013:8 Pages 295—304

DOI http://dx.doi.org/10.2147/COPD.S42366

Received 5 January 2013, Accepted 22 March 2013, Published 27 June 2013

Barbara P Yawn,1 Yunfeng Li,2 Haijun Tian,2 Jie Zhang,2 Steve Arcona,2 Kristijan H Kahler2

1Department of Research, Olmsted Medical Center, Rochester, MN, USA; 2Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Background: The use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) has been associated with an increased risk of pneumonia in controlled clinical trials and case-control analyses.
Objective: Using claims databases as a research model of real-world diagnosis and treatment, to determine if the use and dose of inhaled corticosteroids (ICS) among patients with newly diagnosed COPD are associated with increased risk of pneumonia.
Patients and methods: This was a retrospective cohort analysis of patients diagnosed with COPD between January 01, 2006 and September 30, 2010, drawn from databases (years 2006–2010). Patients (aged ≥45 years) were followed until first pneumonia diagnosis, end of benefit enrollment, or December 31, 2010, whichever was earliest. A Cox proportional hazard model was used to assess the association of ICS use and risk of pneumonia, controlling for baseline characteristics. Daily ICS use was classified into low, medium, and high doses (1 µg–499 µg, 500 µg–999 µg, and ≥1000 µg fluticasone equivalents daily) and was modeled as a time-dependent variable.
Results: Among 135,445 qualifying patients with a total of 243,097 person-years, there were 1020 pneumonia incidences out of 5677 person-years on ICS (crude incidence rate, 0.180 per person-year), and 27,730 pneumonia incidences out of 237,420 person-years not on ICS (crude incidence rate, 0.117 per person-year). ICS use was associated with a dose-related increase in risk of pneumonia, with adjusted hazard ratios (versus no use; (95% confidence interval) of 1.38 (1.27–1.49) for low-dose users, 1.69 (1.52–1.88) for medium-dose users, and 2.57 (1.98–3.33) for high-dose users (P < 0.01 versus no use and between doses).
Conclusion: The use of ICS in newly diagnosed patients with COPD is potentially associated with a dose-related increase in the risk of pneumonia.

Keywords: COPD, ICS, LABA, pneumonia

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Protocol for the asthma tools study: a pragmatic practice-based research network trial

Yawn BP, Bertram S, Kurland M, Wollan P, Graham D, Littlefield D, Smail C, Pace W

Pragmatic and Observational Research 2013, 4:7-18

Published Date: 4 June 2013

Exacerbations in the pre- and post-COPD diagnosis periods

Yawn BP, Wollan P, Rank M

Pragmatic and Observational Research 2013, 4:1-6

Published Date: 2 May 2013

Automated patient and medication payment method for clinical trials

Yawn BP, Madison S, Bertram S, Pace WD, Fuhlbrigge A, Israel E, Littlefield D, Kurland M, Wechsler ME

Open Access Journal of Clinical Trials 2013, 5:23-31

Published Date: 29 January 2013

Introduction of Asthma APGAR tools improve asthma management in primary care practices

Barbara P Yawn, Susan Bertram, Peter Wollan

Journal of Asthma and Allergy 2008, 1:1-10

Published Date: 31 August 2008

Readers of this article also read:

The association between COPD and heart failure risk: a review

de Miguel Díez J, Chancafe Morgan J, Jiménez García R

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:305-312

Published Date: 28 June 2013

Tear cytokine response to multipurpose solutions for contact lenses

Kalsow CM, Reindel WT, Merchea MM, Bateman KM, Barr JT

Clinical Ophthalmology 2013, 7:1291-1302

Published Date: 28 June 2013

Descriptive epidemiology of injuries in a Brazilian premier league soccer team

Fachina RJ, Andrade MS, Silva FR, Waszczuk-Junior S, Montagner PC, Borin JP, de Lira CA

Open Access Journal of Sports Medicine 2013, 4:171-174

Published Date: 27 June 2013

A survey of French general practitioners and a qualitative study on their use and assessment of predictive clinical scores

Sarazin M, Gonzalez Chiappe S, Kasprzyk M, Mismetti P, Lasserre A

International Journal of General Medicine 2013, 6:419-426

Published Date: 25 June 2013

Blood urea nitrogen to serum albumin ratio independently predicts mortality and severity of community-acquired pneumonia

Ugajin M, Yamaki K, Iwamura N, Yagi T, Asano T

International Journal of General Medicine 2012, 5:583-589

Published Date: 12 July 2012

Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity

Joseph Finkelstein, Eunme Cha, Steven M Scharf

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:337-349

Published Date: 4 September 2009